Targeting Macrophages in Glioblastoma: Current Therapies and Future Directions
Cancers · 18.08.2025 · 17 (16) · 2687
DOI: 10.3390/cancers17162687 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.08.2025. Verfasst von Giovanni Pennisi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma (GBM) is an aggressive brain tumor characterized by an immunosuppressive tumor microenvironment (TME), which contributes to treatment resistance and disease progression.
Background
Tumor-associated macrophages (TAMs), comprising both resident microglia and bone marrow–derived macrophages, play a central role in supporting tumor growth, angiogenesis, and immune evasion. Most TAMs adopt an M2-like immunosuppressive phenotype, making them a promising target for immunomodulatory strategies in GBM.
Method
According to PRISMA guidelines, we conducted a systematic literature review and recruited eligible studies focused on therapeutic approaches targeting TAMs in GBM, emphasizing mechanisms of action, efficacy, and challenges. Data extraction focused on therapeutic classes, outcomes, and TAM-related biomarkers.
Results
We identified 30 studies meeting the inclusion criteria. These therapies are categorized into three main strategies: inhibition of TAM recruitment, enhancement of TAM-mediated phagocytosis, and reprogramming of TAMs. Combination strategies, including TAM-targeting with checkpoint inhibitors, nanoparticles, and oncolytic viruses, show synergistic effects in preclinical models.
Conclusions
Targeting TAMs represents a multifaceted strategy for GBM treatment. Current evidence underscores the need for combination approaches integrating TAM modulation with existing standard-of-care therapies. Clinical translation remains limited due to challenges such as TAM heterogeneity, plasticity, immunosuppressive therapies, and restricted drug delivery across the blood–brain barrier. Future directions should highlight personalized treatments based on detailed TME profiling. Combining TAM-targeted therapies with agents modulating metabolic or immune pathways, and leveraging advanced delivery systems and spatial transcriptomics may improve efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
- Department of Neurosurgery, F. Spaziani Hospital, 03100 Frosinone, Italy.
- Department of Neurosurgery, ASST Santi Paolo e Carlo, 20153 Milano, Italy.
- Department of Neurosurgery, San Giovanni-Addolorata Hospital, 00168 Rome, Italy.
ORCID-Profile: Giovanni Pennisi, Federico Valeri, Benedetta Burattini, Placido Bruzzaniti, Giuseppe Maria Della Pepa
Zitieren
APA
Pennisi, G., Valeri, F., Burattini, B., Bruzzaniti, P., Sturiale, C. L., Talacchi, A., Papacci, F., Olivi, A., & Della Pepa, G. M. (2025). Targeting Macrophages in Glioblastoma: Current Therapies and Future Directions. Cancers, 17(16), 2687. https://doi.org/10.3390/cancers17162687
Vancouver
Pennisi G, Valeri F, Burattini B, Bruzzaniti P, Sturiale CL, Talacchi A, et al. Targeting Macrophages in Glioblastoma: Current Therapies and Future Directions. Cancers. 2025;17(16):2687. doi:10.3390/cancers17162687
BibTeX
@article{Pennisi2025,
author = {Pennisi, Giovanni and Valeri, Federico and Burattini, Benedetta and Bruzzaniti, Placido and Sturiale, Carmelo Lucio and Talacchi, Andrea and Papacci, Fabio and Olivi, Alessandro and Della Pepa, Giuseppe Maria},
title = {Targeting Macrophages in Glioblastoma: Current Therapies and Future Directions},
journal = {Cancers},
year = {2025},
volume = {17},
number = {16},
pages = {2687},
doi = {10.3390/cancers17162687}
}
EUVIMED